{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:34:58Z","timestamp":1777592098973,"version":"3.51.4"},"reference-count":87,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Philadelphia-like (Ph-like) acute lymphoblastic leukemia (ALL) is a subgroup of B-cell precursor ALL which by gene expression analysis clusters with Philadelphia-positive ALL although lacking the pathognomonic BCR-ABL1 oncoprotein. Its prevalence increases with age and similar to BCR-ABL1-positive ALL, Ph-like ALL is characterized by IKZF1 or other B-lymphoid transcription factor gene deletions and by poor outcome to conventional therapeutic approaches. Genetic alterations are highly heterogenous across patients and include gene fusions, sequence mutations, DNA copy number changes and cryptic rearrangements. These lesions drive constitutively active cytokine receptor and kinase signaling pathways which deregulate ABL1 or JAK signaling and more rarely other kinase-driven pathways. The presence of activated kinase alterations and cytokine receptors has led to the incorporation of targeted therapy to the chemotherapy backbone which has improved treatment outcome for this high-risk subtype. More recently, retrospective studies have shown the efficacy of immunotherapies including both antibody drug-conjugates and chimeric antigen receptor T cell therapy and as they are not dependent on a specific genetic alteration, it is likely their use will increase in prospective clinical trials. This review summarizes the genomic landscape, clinical features, diagnostic assays, and novel therapeutic approaches for patients with Ph-like ALL.<\/jats:p>","DOI":"10.3390\/genes12050687","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T21:35:39Z","timestamp":1619904939000},"page":"687","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Genetic Alterations and Therapeutic Targeting of Philadelphia-Like Acute Lymphoblastic Leukemia"],"prefix":"10.3390","volume":"12","author":[{"given":"Ilaria","family":"Iacobucci","sequence":"first","affiliation":[{"name":"Department of Pathology, St. Jude Children\u2019s Research Hospital, Memphis, TN 38105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7626-4043","authenticated-orcid":false,"given":"Kathryn G.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Pathology, St. Jude Children\u2019s Research Hospital, Memphis, TN 38105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","article-title":"PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia","volume":"51","author":"Gu","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"E11711","DOI":"10.1073\/pnas.1814397115","article-title":"Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases","volume":"115","author":"Li","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: A genome-wide classification study","volume":"10","author":"Cheok","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion ofIKZF1and Prognosis in Acute Lymphoblastic Leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.beha.2017.07.003","article-title":"The biology of Philadelphia chromosome-like ALL","volume":"30","author":"Roberts","year":"2017","journal-title":"Best Pr. Res. Clin. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/cncr.31848","article-title":"BCR\/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?","volume":"125","author":"Chiaretti","year":"2019","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2018-04-841676","article-title":"Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: A report from the Children\u2019s Oncology Group","volume":"132","author":"Roberts","year":"2018","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2016-12-758979","article-title":"Targetable kinase gene fusions in high-risk B-ALL: A study from the Children\u2019s Oncology Group","volume":"129","author":"Reshmi","year":"2017","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2016.375","article-title":"High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL","volume":"31","author":"Tasian","year":"2017","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: A high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High Frequency and Poor Outcome of Philadelphia Chromosome\u2013Like Acute Lymphoblastic Leukemia in Adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2012-04-422691","article-title":"Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: A report from the Children\u2019s Oncology Group TARGET Project","volume":"121","author":"Loh","year":"2013","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.3324\/haematol.2014.117424","article-title":"Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates","volume":"100","author":"Boer","year":"2015","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3324\/haematol.2015.136366","article-title":"Adults with Philadelphia chromosome\u2013like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis","volume":"102","author":"Herold","year":"2016","journal-title":"Haematologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjh.15251","article-title":"Rapid identification ofBCR\/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: Clinical, prognostic and therapeutic implications","volume":"181","author":"Chiaretti","year":"2018","journal-title":"Br. J. Haematologica"},{"key":"ref_19","unstructured":"Chiaretti, S., Messina, M., Della Starza, I., Piciocchi, A., Cafforio, L., Cavalli, M., Taherinasab, A., Ansuinelli, M., Elia, L., and Petroni, G.A. (2020). Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. Haematologica."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2014.55.4105","article-title":"Outcomes of Children with BCR-ABL1\u2013Like Acute Lymphoblastic Leukemia Treated with Risk-Directed Therapy Based on the Levels of Minimal Residual Disease","volume":"32","author":"Roberts","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e490","DOI":"10.3324\/haematol.2016.162925","article-title":"High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment","volume":"102","author":"Heatley","year":"2017","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-progenitor\u2013 and Down syndrome\u2013associated acute lymphoblastic leukemia","volume":"41","author":"Mullighan","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1073\/pnas.0911726107","article-title":"Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia","volume":"107","author":"Yoda","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/gcc.22439","article-title":"Characterisation of the genomic landscape ofCRLF2-rearranged acute lymphoblastic leukemia","volume":"56","author":"Russell","year":"2017","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","article-title":"Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: A report from the International BFM Study Group","volume":"115","author":"Hertzberg","year":"2010","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.4049\/jimmunol.163.11.5971","article-title":"Requirement for stat5 in thymic stromal lymphopoietin-mediated signal transduction","volume":"163","author":"Isaksen","year":"1999","journal-title":"J. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1515\/bc.2010.029","article-title":"Signal transduction by the atopy-associated human thymic stromal lymphopoietin (TSLP) receptor depends on Janus kinase function","volume":"391","author":"Wohlmann","year":"2010","journal-title":"Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2011-12-389932","article-title":"Aberrant STAT5 and PI3K\/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia","volume":"120","author":"Tasian","year":"2012","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/eji.200939419","article-title":"Thymic stromal lymphopoietin induces early human B-cell proliferation and differentiation","volume":"40","author":"Scheeren","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO.2013.51.3242","article-title":"IGH@ Translocations Are Prevalent in Teenagers and Young Adults with Acute Lymphoblastic Leukemia and Are Associated with a Poor Outcome","volume":"32","author":"Russell","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e26539","DOI":"10.1002\/pbc.26539","article-title":"Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhood","volume":"64","author":"Fedders","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/ajcp\/aqx005","article-title":"CRLF2-Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients: A Single-Institution Experience","volume":"147","author":"Konoplev","year":"2017","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1038\/bcj.2016.28","article-title":"Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan","volume":"6","author":"Imamura","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","article-title":"Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia","volume":"115","author":"Harvey","year":"2010","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/ng.2803","article-title":"Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse","volume":"45","author":"Roberts","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/cncr.30129","article-title":"Childhood leukemia incidence in California: High and rising in the Hispanic population","volume":"122","author":"Giddings","year":"2016","journal-title":"Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1182\/blood-2012-10-462358","article-title":"Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL","volume":"122","author":"Waanders","year":"2013","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1182\/blood-2013-10-529685","article-title":"Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia","volume":"124","author":"Shochat","year":"2014","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ccell.2015.12.013","article-title":"Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia","volume":"29","author":"Iacobucci","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/leu.2008.250","article-title":"A novel translocation, t(14;19)(q32;p13), involving IGH@ and the cytokine receptor for erythropoietin","volume":"23","author":"Russell","year":"2008","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3389\/fonc.2020.00359","article-title":"Rapid Molecular Response to Dasatinib in a Pediatric Relapsed Acute Lymphoblastic Leukemia with NCOR1-LYN Fusion","volume":"10","author":"Dai","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S2352-3026(20)30353-7","article-title":"Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: A multicentre, retrospective, cohort study","volume":"8","author":"Cario","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood.2020008536","article-title":"SSBP2-CSF1R is a Recurrent Fusion in B-lineage Acute Lymphoblastic Leukaemia with Diverse Genetic Presentation and Variable Outcome","volume":"137","author":"Schwab","year":"2020","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1182\/blood-2015-09-670166","article-title":"EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): Genetic profile and clinical implications","volume":"127","author":"Schwab","year":"2016","journal-title":"Blood"},{"key":"ref_45","first-page":"1657","article-title":"Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL","volume":"1","author":"Roberts","year":"2017","journal-title":"Blood Adv."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00277-020-04332-8","article-title":"Effective treatment with imatinib for acute B-lymphoblastic leukaemia with EBF1-PDGFRB fusion","volume":"100","author":"Horiuchi","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/10428194.2019.1668938","article-title":"Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with Ebf1-Pdgfrb fusion transcript","volume":"61","author":"Fazio","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.3324\/haematol.2013.095372","article-title":"Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion","volume":"98","author":"Lengline","year":"2013","journal-title":"Haematologica"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1200\/JCO.2012.47.6770","article-title":"Tyrosine Kinase Inhibitor Therapy Induces Remission in a Patient with Refractory EBF1-PDGFRB\u2013Positive Acute Lymphoblastic Leukemia","volume":"31","author":"Weston","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Tran, T.H., Nguyen, J.V., Stecula, A., Akutagawa, J., Moorman, A.V., Braun, B.S., Sali, A., Mullighan, C.G., Shah, N.P., and Dai, Y. (2021). The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment. Haematologica.","DOI":"10.3324\/haematol.2020.261354"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1182\/blood-2018-05-849554","article-title":"ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition","volume":"132","author":"Roberts","year":"2018","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1746-1596-6-19","article-title":"Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia","volume":"6","author":"Kralik","year":"2011","journal-title":"Diagn. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13000-020-01031-w","article-title":"Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors","volume":"15","author":"Kang","year":"2020","journal-title":"Diagn. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/ng0298-184","article-title":"A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma","volume":"18","author":"Knezevich","year":"1998","journal-title":"Nat. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/cncr.28484","article-title":"ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer","volume":"120","author":"Bs","year":"2014","journal-title":"Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/path.4677","article-title":"Transcriptome sequencing identifiesETV6-NTRK3as a gene fusion involved in GIST","volume":"238","author":"Brenca","year":"2016","journal-title":"J. Pathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1515\/jpem-2017-0292","article-title":"Sporadic pediatric papillary thyroid carcinoma harboring the ETV6\/NTRK3 fusion oncogene in a 7-year-old Japanese girl: A case report and review of literature","volume":"31","author":"Otsubo","year":"2018","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1535-6108(02)00180-0","article-title":"Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma","volume":"2","author":"Tognon","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1200\/JCO.2008.21.6408","article-title":"IKZF1 (Ikaros) Deletions in BCR-ABL1\u2013Positive Acute Lymphoblastic Leukemia Are Associated with Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report","volume":"27","author":"Martinelli","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Raca, G., Abdel-Azim, H., Yue, F., Broach, J., Payne, J.L., Reeves, M.E., Gowda, C., Schramm, J., Desai, D., and Dovat, E. (2021). Increased Incidence of IKZF1 deletions and IGH-CRLF2 translocations in B-ALL of Hispanic\/Latino children\u2014a novel health disparity. Leukemia, 1\u20134.","DOI":"10.1038\/s41375-021-01133-4"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1182\/bloodadvances.2019000769","article-title":"Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement","volume":"4","author":"Nardi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"13331","DOI":"10.1038\/ncomms13331","article-title":"Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia","volume":"7","author":"Gu","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"20055","DOI":"10.1074\/jbc.M010800200","article-title":"The Adaptor Protein BLNK Is Required for B Cell Antigen Receptor-induced Activation of Nuclear Factor-\u03baB and Cell Cycle Entry and Survival of B Lymphocytes","volume":"276","author":"Tan","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1600-065X.2000.imr017518.x","article-title":"Terminal deoxynucleotidyl transferase and repertoire development","volume":"175","author":"Benedict","year":"2000","journal-title":"Immunol. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.3324\/haematol.2015.124941","article-title":"BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: A comparison between DCOG\/Erasmus MC and COG\/St. Jude signatures","volume":"100","author":"Boer","year":"2015","journal-title":"Haematologica"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1182\/blood.V122.21.826.826","article-title":"Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic Leukemia (ALL) Patients with a Philadelphia Chromosome-Like (\u201cPh-like\u201d or \u201cBCR-ABL1-Like\u201d) Signature For Therapeutic Targeting and Clinical Intervention","volume":"122","author":"Harvey","year":"2013","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1182\/blood-2015-08-664649","article-title":"Integrated genomic DNA\/RNA profiling of hematologic malignancies in the clinical setting","volume":"127","author":"He","year":"2016","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/nm.3729","article-title":"Anchored multiplex PCR for targeted next-generation sequencing","volume":"20","author":"Zheng","year":"2014","journal-title":"Nat. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fped.2017.00258","article-title":"Integration of Next-Generation Sequencing to Treat Acute Lymphoblastic Leukemia with Targetable Lesions: The St. Jude Children\u2019s Research Hospital Approach","volume":"5","author":"Inaba","year":"2017","journal-title":"Front. Pediatr."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: Results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(12)70377-7","article-title":"Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): A randomised, open-label, intergroup study","volume":"13","author":"Biondi","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","article-title":"UKALLXII\/ECOG2993: Addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia","volume":"123","author":"Fielding","year":"2014","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"118","author":"Vitale","year":"2011","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children\u2019s Oncology Group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1200\/JCO.2017.76.7228","article-title":"Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome\u2013Positive Acute Lymphoblastic Leukemia: Results of Children\u2019s Oncology Group Trial AALL0622","volume":"36","author":"Slayton","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2018-99-110221","article-title":"A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269\/AALL1521): Dose-Finding Results from the Part 1 Safety Phase","volume":"132","author":"Tasian","year":"2018","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib\u2013Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults","volume":"383","author":"Bassan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjh.17093","article-title":"Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion","volume":"191","author":"Moorman","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.3324\/haematol.2019.231720","article-title":"Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols","volume":"105","author":"Cario","year":"2019","journal-title":"Haematologica"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood.2019001244","article-title":"Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements","volume":"134","author":"Tanasi","year":"2019","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1182\/blood-2012-03-415448","article-title":"Targeting JAK1\/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"120","author":"Maude","year":"2012","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1172\/JCI134424","article-title":"Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL","volume":"130","author":"Hurtz","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2016-05-707653","article-title":"Potent efficacy of combined PI3K\/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.3324\/haematol.2018.192088","article-title":"Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure","volume":"103","author":"Ding","year":"2018","journal-title":"Haematologica"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood.2020006287","article-title":"Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL","volume":"137","author":"Zhao","year":"2021","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1182\/blood-2019-126940","article-title":"Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed\/Refractory (R\/R) Acute Lymphoblastic Leukemia (ALL)","volume":"134","author":"Jabbour","year":"2019","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/12\/5\/687\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:56:36Z","timestamp":1760162196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/12\/5\/687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":87,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["genes12050687"],"URL":"https:\/\/doi.org\/10.3390\/genes12050687","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,1]]}}}